News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
339,242 Results
Type
Article (20466)
Company Profile (128)
Press Release (318648)
Section
Business (109865)
Career Advice (880)
Deals (19119)
Drug Delivery (96)
Drug Development (51448)
Employer Resources (79)
FDA (7748)
Job Trends (7964)
News (191425)
Policy (17641)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Pharm Country Standard (1)
Academia (746)
Accelerated approval (1)
Adcomms (17)
Allergies (36)
Alliances (29740)
ALS (47)
Alzheimer's disease (648)
Antibody-drug conjugate (ADC) (80)
Approvals (7750)
Artificial intelligence (126)
Autoimmune disease (8)
Automation (4)
Bankruptcy (175)
Best Places to Work (5776)
BIOSECURE Act (13)
Biosimilars (84)
Biotechnology (58)
Bladder cancer (28)
Brain cancer (18)
Breast cancer (100)
Cancer (934)
Cardiovascular disease (88)
Career advice (710)
Career pathing (19)
CAR-T (53)
Cell therapy (150)
Cervical cancer (6)
Clinical research (42940)
Collaboration (463)
Compensation (134)
Complete response letters (22)
COVID-19 (1119)
CRISPR (20)
C-suite (121)
Cystic fibrosis (59)
Data (947)
Decentralized trials (2)
Denatured (18)
Depression (21)
Diabetes (128)
Diagnostics (1841)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (68)
Drug pricing (108)
Drug shortages (29)
Duchenne muscular dystrophy (45)
Earnings (41246)
Editorial (26)
Employer branding (10)
Employer resources (73)
Events (48638)
Executive appointments (382)
FDA (8227)
Featured Employer (24)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (272)
Gene editing (43)
Generative AI (17)
Gene therapy (134)
GLP-1 (560)
Government (1840)
Grass and pollen (2)
Guidances (18)
Healthcare (6096)
Huntington's disease (13)
IgA nephropathy (18)
Immunology and inflammation (64)
Indications (14)
Infectious disease (1191)
Inflammatory bowel disease (82)
Inflation Reduction Act (8)
Influenza (21)
Intellectual property (47)
Interviews (116)
IPO (7628)
IRA (45)
Job creations (2453)
Job search strategy (648)
Kidney cancer (7)
Labor market (17)
Layoffs (278)
Leadership (13)
Legal (4273)
Liver cancer (30)
Lung cancer (141)
Lymphoma (77)
Machine learning (2)
Management (30)
Manufacturing (173)
MASH (42)
Medical device (2080)
Medtech (2083)
Mergers & acquisitions (11693)
Metabolic disorders (437)
Multiple sclerosis (40)
NASH (20)
Neurodegenerative disease (42)
Neuropsychiatric disorders (19)
Neuroscience (920)
NextGen: Class of 2025 (2393)
Non-profit (913)
Northern California (984)
Now hiring (19)
Obesity (272)
Opinion (189)
Ovarian cancer (29)
Pain (59)
Pancreatic cancer (34)
Parkinson's disease (70)
Partnered (8)
Patents (119)
Patient recruitment (37)
Peanut (15)
People (33393)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (13439)
Phase II (18189)
Phase III (14619)
Pipeline (546)
Podcasts (65)
Policy (96)
Postmarket research (1621)
Preclinical (4678)
Press Release (29)
Prostate cancer (53)
Psychedelics (17)
Radiopharmaceuticals (162)
Rare diseases (227)
Real estate (3183)
Recruiting (29)
Regulatory (12561)
Reports (22)
Research institute (837)
Resumes & cover letters (138)
RSV (25)
Schizophrenia (54)
Series A (54)
Series B (26)
Service/supplier (6)
Sickle cell disease (34)
Southern California (926)
Special edition (14)
Sponsored (12)
Startups (2043)
State (2)
Stomach cancer (8)
Supply chain (48)
The Weekly (46)
United States (9085)
Vaccines (263)
Venture capitalists (25)
Webinars (11)
Weight loss (222)
Women's health (14)
Worklife (6)
Date
Today (82)
Last 7 days (392)
Last 30 days (1587)
Last 365 days (17929)
2025 (3059)
2024 (18187)
2023 (20265)
2022 (26514)
2021 (27270)
2020 (25510)
2019 (20437)
2018 (16004)
2017 (17601)
2016 (16512)
2015 (19284)
2014 (15118)
2013 (12761)
2012 (13709)
2011 (14050)
2010 (12995)
Location
Africa (410)
Alabama (23)
Alaska (1)
Arizona (57)
Arkansas (8)
Asia (25295)
Australia (3307)
California (2289)
Canada (1032)
China (275)
Colorado (89)
Connecticut (96)
Delaware (64)
Europe (52284)
Florida (375)
Georgia (52)
Idaho (16)
Illinois (221)
India (15)
Indiana (160)
Iowa (2)
Japan (100)
Kansas (60)
Kentucky (17)
Louisiana (1)
Maine (4)
Maryland (336)
Massachusetts (1918)
Michigan (47)
Minnesota (123)
Mississippi (1)
Missouri (25)
Montana (11)
Nebraska (11)
Nevada (15)
New Hampshire (8)
New Jersey (888)
New Mexico (20)
New York (652)
North Carolina (466)
North Dakota (2)
Northern California (984)
Ohio (79)
Oklahoma (5)
Oregon (21)
Pennsylvania (517)
Puerto Rico (7)
Rhode Island (11)
South America (617)
South Carolina (5)
Southern California (926)
Tennessee (32)
Texas (301)
Utah (55)
Virginia (74)
Washington D.C. (40)
Washington State (193)
Wisconsin (17)
339,242 Results for "royalty pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Biogen Taps Royalty Pharma for $250M to Power Phase III Lupus Program
The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the company’s forecasted dip in 2025 revenues.
February 12, 2025
·
2 min read
·
Tristan Manalac
Business
Royalty Pharma Drops $525M for Royalties and Milestones on Sanofi-Licensed MS Therapy
With its $525 million investment, Royalty Pharma will acquire the royalties and milestones for ImmuNext’s anti-CD40 therapy frexalimab, which is currently in Phase III trials for multiple sclerosis.
May 10, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
November 5, 2024
·
12 min read
Biotech Beach
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
Arrowhead Pharmaceuticals, Inc. announced a $50 million milestone payment was received from Royalty Pharma plc.
May 2, 2024
·
6 min read
Press Releases
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
November 7, 2024
·
7 min read
Pharm Country
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
Ascendis Pharma A/S and Royalty Pharma plc announced that Ascendis has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net SKYTROFA revenue.
September 5, 2023
·
10 min read
Press Releases
Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan
January 20, 2025
·
6 min read
Government
Trump Threatens Big Pharma With Tariffs—Unless They Reshore Manufacturing: Bloomberg
President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.
February 24, 2025
·
2 min read
·
Tristan Manalac
C-suite
GSK CEO Emma Walmsley Gets Pay Bump To Align With Pharma Peers
One of the lowest paid CEOs in pharma—and one of the only woman leading a top-tier giant—is set to receive up to $27.2 million in 2025.
February 27, 2025
·
2 min read
·
Annalee Armstrong
Pharm Country
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
PTC Therapeutics, Inc. announced an agreement with Royalty Pharma plc. to monetize up to $1.5 billion of the Evrysdi royalty stream.
October 19, 2023
·
6 min read
1 of 33,925
Next
